| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Cellectar Biosciences Inc. | Iopofosine (CLR 131) - (CLOVER-WaM) | Waldenstrom’s macroglobulinemia (WM) | Phase 2b | Data Released | Intravenous | Hematology |
| Cellectis S.A. | ALLO-501/501A + ALLO-647 - (ALPHA2) | Large B-cell lymphoma | Phase 2 | Data Released | intravenous | Oncology |
| Celularity Inc. | PDA-002 | Diabetic Foot Ulcer | Phase 2 | Data Released | Intramuscular injection | Wound Care |
| Centessa Pharmaceuticals plc | SerpinPC - (PRESent-3) | Hemophilia B | Phase 2b | Data Released | Subcutaneous | Hematology |
| Centessa Pharmaceuticals plc | ORX750 - (CRYSTAL-1) | Narcolepsy and other sleep-wake disorders | Phase 3 | Trial Planned | oral | Neurology |
| Centessa Pharmaceuticals plc | Imgatuzumab (I-PACE) | Cutaneous squamous cell carcinoma (CSCC) | Phase 2 | Trial Planned | Intravenous | Oncology |
| Centessa Pharmaceuticals plc | Lixivaptan - (ALERT) | Kidney Disease | Phase 3 | Trial Discontinued | Oral | N/A |
| Centessa Pharmaceuticals plc | Lixivaptan - (ACTION) | Autosomal dominant polycystic kidney disease (ADPKD) | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |